Epigenomics AG: Planned capital reduction in a ratio of 4:1

DGAP-Ad-hoc: Epigenomics AG / Keyword(s): Corporate Action/AG/AGE
Epigenomics AG: Planned capital reduction in a ratio of 4:1

09-Sep-2022 / 19:19 CET/CEST
Disclosure of privileged information according to. in Article 17 MAR of Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Epigenomics AG: Planned capital reduction in a ratio of 4:1

Berlin, September 9, 2022 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) plans to propose to the Extraordinary General Meeting, which is to be convened on October 21, 2022 and held as a virtual general meeting without the physical presence of Shareholders or their representatives, in addition to the declaration of loss pursuant to Article 92 para. 1 AktG, the reduction of the share capital to one quarter of the share capital at the General Meeting.

The capital reduction must take place in two stages. Initially, the share capital will be reduced by withdrawing a maximum of three treasury shares acquired free of charge so that the share capital is a multiple of four. On the other hand, the share capital of the Company will be reduced to a quarter by means of an ordinary reduction of the capital in accordance with articles 222 and following. AktG. The ordinary capital reduction will be carried out by consolidation of the Company’s shares in the ratio 4:1 and will serve partly to cover losses and partly to provide the Company’s capital reserves.

The specific amount of the capital reduction depends on the amount of the share capital on the date of the Extraordinary General Meeting of October 21, 2022 which in turn depends on whether and to what extent the holders of convertible bonds issued by the Company exercise their conversion rights at the conversion window at the beginning of October 2022. Based on the share capital to date of an amount of EUR 16,357,482.00 the share capital would be reduced by EUR 2.00 to EUR 16,357,480.00 per withdrawal of shares then from EUR 12,268,110.00 to EUR 4,089,370.00 by combining shares.

The complete agenda, as well as further explanations and information on registration for the Extraordinary General Meeting of Shareholders, can be found in the convocation, which should be published in the Federal Official Gazette on September 14, 2022 and will also be available on https://www.epigenomics.com/news-investors/general-shareholder-meeting/.

Contact:

Company

Epigenomics AG, Geneststrasse 5, 10829 Berlin

Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email: [email protected]

Investor Relations

IR.on AG, Frederic Hilke, tel. +49 221 9140 970, email: [email protected]

Note on forward-looking statements

This publication expressly or implicitly contains forward-looking statements regarding Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause the actual results, financial condition and performance of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied. understood by these statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.

09-Sep-2022 CET/CEST DGAP distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at www.dgap.de

Sallie R. Loera